Rivanicline

Rivanicline
Clinical data
ATC code	none;
Identifiers
	IUPAC name (E)-N-Methyl-4-(3-pyridinyl)-3-butene-1-amine;
CAS Number	15585-43-0 ; 538-79-4 (Mixture E of Z);
PubChem CID	5310967;
IUPHAR/BPS	3994;
ChemSpider	4470511 ;
UNII	6H35LF645A;
CompTox Dashboard (EPA)	DTXSID101017740 ;
Chemical and physical data
Formula	C10H14N2
Molar mass	162.236 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNCC\C=C\C1=CN=CC=C1;
	InChI InChI=1S/C10H14N2/c1-11-7-3-2-5-10-6-4-8-12-9-10/h2,4-6,8-9,11H,3,7H2,1H3/b5-2+ ; Key:JUOSGGQXEBBCJB-GORDUTHDSA-N ;
	(what is this?) (verify)

Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease,^[1]^[2]^[3] but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis.^[4] Rivanicline also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release,^[5] and so it could also have other applications. It has been identified as constituent of tobacco as well.^[6]^[7]